Pentixapharm has agreed to acquire the Glycotope business unit focusing on target discovery, expanding its IP portfolio
The acquisition includes Glycotope’s portfolio of preclinical Abs for oncology targets with the potential to be developed into radiopharmaceuticals, laboratories, cell banks, tumor target database & equipment for discovery platform plus various patents, licenses & other assets
The discovery unit is built upon a technology platform utilized to develop tumor-specific mAbs or fragments targeting tumor-linked carbohydrate structures or protein/carbohydrate combined glycoepitopes (GlycoTargets)
Ref: Pentixapharm | Image: Pentixapharm
Related News: LegoChem Entered into a Research Collaboration and License Agreement with Glycotope to Develop ADCs for the Treatment of Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
